• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Septerna Inc.

    4/29/25 4:08:35 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email
    DEFA14A 1 d713134ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    (RULE 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

    Filed by the Registrant  ☒

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    SEPTERNA, INC.

     

     

    (Name of Registrant as Specified In Its Charter)

     

       

     

    (Name of person(s) filing proxy statement, if other than the registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    Vote Counts! SEPTERNA, INC. 2025 Annual Meeting of Stockholders To be held Online on June 17, 2025 Vote by June 16, 2025 11:59 PM ET SEPTERNA, INC. 250 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080 V71496-P29068 Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting To Be Held on June 17, 2025. You invested in SEPTERNA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. Get informed before you vote View the Notice, Proxy Statement and 2024 Annual Report online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to June 3, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 (toll-free from the U.S., U.S. territories and Canada) or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 17, 2025 2:00 PM PST vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/SEPN2025 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming 2025 Annual Meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. Election of Directors Nominees: 1a. Abraham Bassan, M.S. For 1b. Alan Ezekowitz, M.D., D. Phil. For 2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm For for the fiscal year ending December 31, 2025. NOTE: In their discretion, proxies are authorized to vote upon such other business as may properly come before the 2025 Annual Meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V71497-P29068

    Get the next $SEPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

      Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results. "Our Native Comp

      3/27/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna to Present at TD Cowen 45th Annual Health Care Conference

      SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development

      2/26/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

      Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism.

      2/18/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Finer Jeffrey exercised 55,000 shares at a strike of $2.76, increasing direct ownership by 7% to 826,907 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      4/4/25 4:13:25 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/10/25 4:18:19 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/6/25 9:02:51 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SEPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/10/25 4:18:19 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/6/25 9:02:51 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Finer Jeffrey bought $96,961 worth of shares (17,000 units at $5.70), increasing direct ownership by 2% to 771,907 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      2/27/25 6:53:01 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

      2/18/25 8:55:10 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on Septerna with a new price target

      Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

      11/19/24 7:39:27 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Septerna

      TD Cowen initiated coverage of Septerna with a rating of Buy

      11/19/24 7:39:11 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Leadership Updates

    Live Leadership Updates

    See more
    • Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins

      1/6/25 7:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Septerna Inc.

      SC 13D - Septerna, Inc. (0001984086) (Subject)

      11/4/24 4:39:38 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Septerna Inc.

      SC 13G - Septerna, Inc. (0001984086) (Subject)

      11/4/24 4:15:38 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Septerna Inc.

      SC 13G - Septerna, Inc. (0001984086) (Subject)

      11/1/24 4:27:45 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Septerna Inc.

      DEFA14A - Septerna, Inc. (0001984086) (Filer)

      4/29/25 4:08:35 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Septerna Inc.

      DEF 14A - Septerna, Inc. (0001984086) (Filer)

      4/29/25 4:05:26 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Septerna Inc.

      S-8 - Septerna, Inc. (0001984086) (Filer)

      3/27/25 8:51:02 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care